Progyny Inc (PGNY)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Progyny Inc (PGNY) Financials: Revenue, Profit and Cash Flow
Progyny reported revenue of $1.29B for the fiscal year ended Dec 31, 2025, up 10.4% from the year before. That year, net income was $58.52M with a net margin of 4.5%, operating cash flow was $210.19M and free cash flow was $191.78M. The quarter ended Sep 30, 2026 had revenue of $341.25M and net income of $26.25M.
Revenue and Margins
The operating margin was 6.6% in the fiscal year ended Dec 2025, the highest of the 9 years shown. Over the 8 years to Dec 2025, revenue grew from $48.58M, a compound annual rate of 50.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.29B | +10.4% | 23.6% | 6.6% | 4.5% |
| Dec 2024 | $1.17B | +7.2% | 21.7% | 5.8% | 4.7% |
| Dec 2023 | $1.09B | +38.3% | 21.9% | 5.7% | 5.7% |
| Dec 2022 | $786.91M | +57.2% | 21.3% | 3.0% | 3.9% |
| Dec 2021 | $500.62M | +45.2% | 22.4% | 6.5% | 13.1% |
| Dec 2020 | $344.86M | +50.1% | 20.3% | 2.4% | 13.5% |
| Dec 2019 | $229.68M | +117.9% | 19.8% | 4.2% | -3.7% |
| Dec 2018 | $105.40M | +116.9% | 18.4% | -3.3% | 0.6% |
| Dec 2017 | $48.58M | N/A | 15.2% | -22.7% | -25.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 7.7% from the year before. In the quarter ended Sep 2026, net income rose 89.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.09B | $786.91M | $500.62M | $344.86M | $229.68M | $105.40M | $48.58M |
| Cost of revenue | $984.18M | $913.86M | $849.80M | $619.59M | $388.49M | $274.80M | $184.18M | $85.97M | $41.18M |
| Gross profit | $304.48M | $253.36M | $238.80M | $167.32M | $112.14M | $70.06M | $45.51M | $19.43M | $7.40M |
| Operating income | $85.28M | $67.45M | $62.18M | $23.34M | $32.34M | $8.35M | $9.68M | -$3.45M | -$11.01M |
| Net income | $58.52M | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M | -$8.57M | $661.00K | -$12.45M |
| EBITDA | $100.38M | $86.38M | $72.97M | $26.04M | $33.27M | $10.46M | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $341.25M | $350.51M | $328.50M | $318.40M | $313.35M | $332.87M | $324.04M | $298.43M | $286.63M | $304.09M | $278.08M | $269.94M |
| Gross profit | $83.74M | $89.30M | $83.07M | $76.88M | $72.83M | $78.97M | $75.80M | $63.43M | $59.24M | $68.28M | $62.41M | $56.89M |
| Operating income | $35.18M | $40.00M | $35.38M | $15.22M | $21.53M | $24.36M | $24.17M | $15.79M | $12.46M | $20.69M | $18.52M | $13.80M |
| Net income | $26.25M | $28.05M | $24.23M | $12.48M | $13.86M | $17.11M | $15.06M | $10.53M | $10.42M | $16.48M | $16.90M | $13.47M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $3.73M by $108.51M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $742.43M | $607.10M | $756.62M | $542.99M | $358.06M | $253.93M | $150.43M | $41.32M | $34.96M |
| Current assets | $551.77M | $472.72M | $640.41M | $433.86M | $258.54M | $190.22M | $132.44M | $24.54M | $16.77M |
| Cash and equivalents | $112.24M | $162.31M | $97.30M | $120.08M | $91.41M | $70.31M | $80.38M | $127.00K | $4.69M |
| Total liabilities | $226.39M | $185.04M | $203.19M | $166.02M | $106.24M | $86.98M | $36.16M | $30.20M | $24.27M |
| Short-term debt | $3.73M | $2.86M | $2.15M | $1.23M | $1.23M | $1.23M | N/A | $253.00K | $3.56M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.63M |
| Shareholder equity | $516.04M | $422.06M | $553.43M | $376.97M | $251.82M | $166.95M | $114.27M | -$95.11M | $10.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $675.79M | $715.84M | $698.34M | $742.43M | $795.23M | $760.95M | $730.28M | $607.10M | $659.97M | $698.63M | $794.30M | $756.62M |
| Total liabilities | $261.76M | $262.58M | $258.99M | $226.39M | $235.22M | $245.93M | $263.13M | $185.04M | $225.10M | $242.44M | $222.70M | $203.19M |
| Cash and equivalents | $116.82M | $152.63M | $131.61M | $112.24M | $133.98M | $132.51M | $109.24M | $162.31M | $91.48M | $94.96M | $114.96M | $97.30M |
| Shareholder equity | $414.03M | $453.26M | $439.34M | $516.04M | $560.00M | $515.02M | $467.16M | $422.06M | $434.88M | $456.19M | $571.60M | $553.43M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 91.2% of operating cash flow. Share repurchases came to 42.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $210.19M | $179.10M | $188.81M | $80.39M | $26.04M | $36.20M | -$1.53M | $2.27M | -$9.47M |
| Capital expenditures | $18.41M | $5.41M | $3.64M | $3.24M | $2.13M | $1.04M | $2.96M | $579.00K | $612.00K |
| Free cash flow | $191.78M | $173.70M | $185.17M | $77.15M | $23.91M | $35.17M | -$4.49M | $1.69M | -$10.09M |
| Share repurchases | $81.66M | $300.28M | $0 | $0 | N/A | $892.00K | $3.02M | $1.21M | $0 |
| Investing cash flow | -$159.01M | $195.79M | -$200.53M | -$43.87M | $8.77M | -$40.03M | -$2.76M | $1.90M | -$612.00K |
| Financing cash flow | -$99.36M | -$309.88M | -$11.07M | -$7.86M | -$13.70M | -$6.25M | $84.55M | -$8.74M | $11.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56.60M | $50.42M | $45.95M | $54.20M | $50.67M | $55.51M | $49.81M | $52.16M | $44.52M | $56.69M | $25.73M | $37.66M |
| Capital expenditures | $9.37M | $6.22M | $6.35M | $5.61M | $4.68M | $5.27M | $2.84M | $1.90M | $1.79M | $866.00K | $850.00K | $553.00K |
| Free cash flow | $47.24M | $44.21M | $39.60M | $48.59M | $45.99M | $50.24M | $46.97M | $50.27M | $42.72M | $55.83M | $24.88M | $37.11M |
Frequently Asked Questions About PGNY
What is Progyny's annual revenue?
Progyny reported revenue of $1.29B for the fiscal year ended Dec 31, 2025.
How fast is Progyny's revenue growing?
Revenue was up 10.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.9%.
Is Progyny profitable?
Yes. Progyny reported net income of $58.52M for the fiscal year ended Dec 31, 2025, with a net margin of 4.5%.
How much free cash flow does PGNY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $210.19M minus capital expenditures of $18.41M produced free cash flow of $191.78M.
How much debt does Progyny have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.73M and cash and equivalents of $112.24M.
PGNY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors